Drugs / CAP7.1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02094560 | Nov 2011 → Sep 2015 | cancer | CellAct Pharma GmbH | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAP7.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02094560 ↗ |
| Route | Intravenous | “Eligible adult patients with advanced, refractory, solid malignancies received CAP7.1 as intravenous infusion on 5 consecutive days.” PMID 28531881 ↗ May 2017 |